Food and Drug Administration, HHS Pt. 212

Size: px
Start display at page:

Download "Food and Drug Administration, HHS Pt. 212"

Transcription

1 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS Pt. 212 investigation was found not to be necessary and the name of the responsible person making such a determination. [43 FR 45077, Sept. 29, 1978, as amended at 51 FR 24479, July 3, 1986; 68 FR 15364, Mar. 31, 2003] Subpart K Returned and Salvaged Drug Products Returned drug products. Returned drug products shall be identified as such and held. If the conditions under which returned drug products have been held, stored, or shipped before or during their return, or if the condition of the drug product, its container, carton, or labeling, as a result of storage or shipping, casts doubt on the safety, identity, strength, quality or purity of the drug product, the returned drug product shall be destroyed unless examination, testing, or other investigations prove the drug product meets appropriate standards of safety, identity, strength, quality, or purity. A drug product may be reprocessed provided the subsequent drug product meets appropriate standards, specifications, and characteristics. Records of returned drug products shall be maintained and shall include the name and label potency of the drug product dosage form, lot number (or control number or batch number), reason for the return, quantity returned, date of disposition, and ultimate disposition of the returned drug product. If the reason for a drug product being returned implicates associated batches, an appropriate investigation shall be conducted in accordance with the requirements of Procedures for the holding, testing, and reprocessing of returned drug products shall be in writing and shall be followed Drug product salvaging. Drug products that have been subjected to improper storage conditions including extremes in temperature, humidity, smoke, fumes, pressure, age, or radiation due to natural disasters, fires, accidents, or equipment failures shall not be salvaged and returned to the marketplace. Whenever there is a question whether drug products have been subjected to such conditions, salvaging operations may be conducted only if there is (a) evidence from laboratory tests and assays (including animal feeding studies where applicable) that the drug products meet all applicable standards of identity, strength, quality, and purity and (b) evidence from inspection of the premises that the drug products and their associated packaging were not subjected to improper storage conditions as a result of the disaster or accident. Organoleptic examinations shall be acceptable only as supplemental evidence that the drug products meet appropriate standards of identity, strength, quality, and purity. Records including name, lot number, and disposition shall be maintained for drug products subject to this section. PART 212 CURRENT GOOD MAN- UFACTURING PRACTICE FOR POSITRON EMISSION TOMOG- RAPHY DRUGS Subpart A General Provisions Sec What are the meanings of the technical terms used in these regulations? What is current good manufacturing practice for PET drugs? To what drugs do the regulations in this part apply? Subpart B Personnel and Resources What personnel and resources must I have? Subpart C Quality Assurance What activities must I perform to ensure drug quality? Subpart D Facilities and Equipment What requirements must my facilities and equipment meet? Subpart E Control of Components, Containers, and Closures How must I control the components I use to produce PET drugs and the containers and closures I package them in? Subpart F Production and Process Controls What production and process controls must I have? VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

2 CFR Ch. I ( Edition) erowe on DSK2VPTVN1PROD with CFR Subpart G Laboratory Controls What requirements apply to the laboratories where I test components, inprocess materials, and finished PET drug products? What must I do to ensure the stability of my PET drug products through expiry? Subpart H Finished Drug Product Controls and Acceptance Criteria What controls and acceptance criteria must I have for my finished PET drug products? What actions must I take if a batch of PET drug product does not conform to specifications? Subpart I Packaging and Labeling What are the requirements associated with labeling and packaging PET drug products? Subpart J Distribution What actions must I take to control the distribution of PET drug products? Subpart K Complaint Handling What do I do if I receive a complaint about a PET drug product produced at my facility? Subpart L Records How must I maintain records of my production of PET drugs? AUTHORITY: 21 U.S.C. 321, 351, 352, 355, 371, 374; Sec. 121, Pub. L , 111 Stat SOURCE: 74 FR 65431, Dec. 10, 2009, unless otherwise noted. Subpart A General Provisions What are the meanings of the technical terms used in these regulations? The following definitions apply to words and phrases as they are used in this part. Other definitions of these words may apply when they are used in other parts of this chapter. Acceptance criteria means numerical limits, ranges, or other criteria for tests that are used for or in making a decision to accept or reject a unit, lot, or batch of a PET drug product. Act means the Federal Food, Drug, and Cosmetic Act, as amended (21 U.S.C. 321 et seq.). 172 Active pharmaceutical ingredient means a substance that is intended for incorporation into a finished PET drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis or monitoring of a disease or a manifestation of a disease in humans, but does not include intermediates used in the synthesis of such substance. Batch means a specific quantity of PET drug intended to have uniform character and quality, within specified limits, that is produced according to a single production order during the same cycle of production. Batch production and control record means a unique record that references an accepted master production and control record and documents specific details on production, labeling, and quality control for a single batch of a PET drug. Component means any ingredient intended for use in the production of a PET drug, including any ingredients that may not appear in the final PET drug product. Conditional final release means a final release made prior to completion of a required finished-product test because of a malfunction involving analytical equipment. Final release means the authoritative decision by a responsible person in a PET production facility to permit the use of a batch of a PET drug in humans. Inactive ingredient means any intended component of the PET drug other than the active pharmaceutical ingredient. In-process material means any material fabricated, compounded, blended, or derived by chemical reaction that is produced for, and is used in, the preparation of a PET drug. Lot means a batch, or a specifically identified portion of a batch, having uniform character and quality within specified limits. In the case of a PET drug produced by continuous process, a lot is a specifically identified amount produced in a unit of time or quantity in a manner that ensures its having uniform character and quality within specified limits. VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

3 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS Lot number, control number, or batch number means any distinctive combination of letters, numbers, or symbols from which the complete history of the production, processing, packing, holding, and distribution of a batch or lot of a PET drug can be determined. Master production and control record means a compilation of instructions containing the procedures and specifications for the production of a PET drug. Material release means the authoritative decision by a responsible person in a PET production facility to permit the use of a component, container and closure, in-process material, packaging material, or labeling in the production of a PET drug. PET means positron emission tomography. PET drug means a radioactive drug that exhibits spontaneous disintegration of unstable nuclei by the emission of positrons and is used for providing dual photon positron emission tomographic diagnostic images. The definition includes any nonradioactive reagent, reagent kit, ingredient, nuclide generator, accelerator, target material, electronic synthesizer, or other apparatus or computer program to be used in the preparation of a PET drug. PET drug includes a PET drug product as defined in this section. PET drug product means a finished dosage form of a PET drug, whether or not in association with one or more other ingredients. PET drug production facility means a facility that is engaged in the production of a PET drug. Production means the manufacturing, compounding, processing, packaging, labeling, reprocessing, repacking, relabeling, and testing of a PET drug. Quality assurance means a system for ensuring the quality of active ingredients, PET drugs, intermediates, components that yield an active pharmaceutical ingredient, analytical supplies, and other components, including container-closure systems and in-process materials, through procedures, tests, analytical methods, and acceptance criteria. Receiving facility means any hospital, institution, nuclear pharmacy, imaging facility, or other entity or part of an 173 entity that accepts a PET drug product that has been given final release, but does not include a common or contract carrier that transports a PET drug product from a PET production facility to a receiving facility. Specifications means the tests, analytical procedures, and appropriate acceptance criteria to which a PET drug, PET drug product, component, container-closure system, in-process material, or other material used in PET drug production must conform to be considered acceptable for its intended use. Conformance to specifications means that a PET drug, PET drug product, component, container-closure system, in-process material, or other material used in PET drug production, when tested according to the described analytical procedures, meets the listed acceptance criteria. Strength means the concentration of the active pharmaceutical ingredient (radioactivity amount per volume or weight at the time of calibration). Sub-batch means a quantity of PET drug having uniform character and quality, within specified limits, that is produced during one succession of multiple irradiations, using a given synthesis and/or purification operation. Verification means confirmation that an established method, process, or system meets predetermined acceptance criteria What is current good manufacturing practice for PET drugs? Current good manufacturing practice for PET drugs is the minimum requirements for the methods to be used in, and the facilities and controls used for, the production, quality assurance, holding, or distribution of PET drugs intended for human use. Current good manufacturing practice is intended to ensure that each PET drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, that it is supposed to have To what drugs do the regulations in this part apply? (a) Application solely to PET drugs. The regulations in this part apply only to the production, quality assurance, holding, and distribution of PET drugs. VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

4 Any human drug that does not meet the definition of a PET drug must be manufactured in accordance with the current good manufacturing practice requirements in parts 210 and 211 of this chapter. (b) Investigational and research PET drugs. For investigational PET drugs for human use produced under an investigational new drug application in accordance with part 312 of this chapter, and PET drugs produced with the approval of a Radioactive Drug Research Committee in accordance with part 361 of this chapter, the requirement under the act to follow current good manufacturing practice is met by complying with the regulations in this part or by producing PET drugs in accordance with Chapter 823, Radiopharmaceuticals for Positron Emission Tomography Compounding, May 1, 2009, pp , 32d ed. of the United States Pharmacopeia (USP) National Formulary (NF) (USP 32/NF 27) (2009). The Director of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain a copy from the United States Pharmacopeial Convention, Inc., Twinbrook Pkwy., Rockville, MD 20852, Geeta M. Tirumalai, , e- mail: gt@usp.org, Internet address: You may inspect a copy at the Food and Drug Administration Biosciences Library, New Hampshire Ave., Silver Spring, MD, , , or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call , or go to federallregister/ codeloflfederallregulations/ ibrllocations.html. 21 CFR Ch. I ( Edition) What personnel and resources must I have? You must have a sufficient number of personnel with the necessary education, background, training, and experience to perform their assigned functions. You must have adequate resources, including facilities and equipment, to enable your personnel to perform their functions. Subpart C Quality Assurance What activities must I perform to ensure drug quality? (a) Production operations. You must oversee production operations to ensure that each PET drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, that it is supposed to have. (b) Materials. You must examine and approve or reject components, containers, closures, in-process materials, packaging materials, labeling, and finished dosage forms to ensure compliance with procedures and specifications affecting the identity, strength, quality, or purity of a PET drug. (c) Specifications and processes. You must approve or reject, before implementation, any initial specifications, methods, processes, or procedures, and any proposed changes to existing specifications, methods, processes, or procedures, to ensure that they maintain the identity, strength, quality, and purity of a PET drug. You must demonstrate that any change does not adversely affect the identity, strength, quality, or purity of any PET drug. (d) Production records. You must review production records to determine whether errors have occurred. If errors have occurred, or a production batch or any component of the batch fails to meet any of its specifications, you must determine the need for an investigation, conduct investigations when necessary, and take appropriate corrective actions. (e) Quality assurance. You must establish and follow written quality assurance procedures. erowe on DSK2VPTVN1PROD with CFR Subpart B Personnel and Resources 174 Subpart D Facilities and Equipment What requirements must my facilities and equipment meet? (a) Facilities. You must provide adequate facilities to ensure the orderly handling of materials and equipment, the prevention of mix-ups, and the prevention of contamination of equipment or product by substances, personnel, or VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

5 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS environmental conditions that could reasonably be expected to have an adverse effect on product quality. (b) Equipment procedures. You must implement procedures to ensure that all equipment that could reasonably be expected to adversely affect the identity, strength, quality, or purity of a PET drug, or give erroneous or invalid test results when improperly used or maintained, is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results. You must document your activities in accordance with these procedures. (c) Equipment construction and maintenance. Equipment must be constructed and maintained so that surfaces that contact components, in-process materials, or PET drugs are not reactive, additive, or absorptive so as to alter the quality of PET drugs. Subpart E Control of Components, Containers, and Closures How must I control the components I use to produce PET drugs and the containers and closures I package them in? (a) Written procedures. You must establish, maintain, and follow written procedures describing the receipt, login, identification, storage, handling, testing, and acceptance and/or rejection of components and drug product containers and closures. The procedures must be adequate to ensure that the components, containers, and closures are suitable for their intended use. (b) Written specifications. You must establish appropriate written specifications for the identity, quality, and purity of components and for the identity and quality of drug product containers and closures. (c) Examination and testing. Upon receipt, each lot of components and containers and closures must be uniquely identified and tested or examined to determine whether the lot complies with your specifications. You must not use in PET drug production any lot that does not meet its specifications, including any expiration date if applicable, or that has not yet received its 175 material release. Any incoming lot must be appropriately designated as quarantined, accepted, or rejected. You must use a reliable supplier as a source of each lot of each component, container, and closure. (1)(i) If you conduct finished-product testing of a PET drug product that includes testing to ensure that the correct components have been used, you must determine that each lot of incoming components used in that PET drug product complies with written specifications by examining a certificate of analysis provided by the supplier. You are not required to perform a specific identity test on any of those components. (ii) If you do not conduct finishedproduct testing of a PET drug product that ensures that the correct components have been used, you must conduct identity testing on each lot of a component that yields an active ingredient and each lot of an inactive ingredient used in that PET drug product. This testing must be conducted using tests that are specific to each component that yields an active ingredient and each inactive ingredient. For any other component, such as a solvent or reagent, that is not the subject of finished-product testing, you must determine that each lot complies with written specifications by examining a certificate of analysis provided by the supplier; if you use such a component to prepare an inactive ingredient on site, you must perform an identity test on the components used to make the inactive ingredient before the components are released for use. However, if you use as an inactive ingredient a product that is approved under section 505 of the act (21 U.S.C. 355) and is marketed as a finished drug product intended for intravenous administration, you need not perform a specific identity test on that ingredient. (2) You must examine a representative sample of each lot of containers and closures for conformity to its written specifications. You must perform at least a visual identification of each lot of containers and closures. (d) Handling and storage. You must handle and store components, containers, and closures in a manner that prevents contamination, mix-ups, and VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

6 CFR Ch. I ( Edition) erowe on DSK2VPTVN1PROD with CFR deterioration and ensures that they are and remain suitable for their intended use. (e) Records. You must keep a record for each shipment of each lot of components, containers, and closures that you receive. The record must include the identity and quantity of each shipment, the supplier s name and lot number, the date of receipt, the results of any testing performed, the disposition of rejected material, and the expiration date (where applicable). Subpart F Production and Process Controls What production and process controls must I have? You must have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity. (a) Written control procedures. You must have written production and process control procedures to ensure and document that all key process parameters are controlled and that any deviations from the procedures are justified. (b) Master production and control records. You must have master production and control records that document all steps in the PET drug production process. The master production and control records must include the following information: (1) The name and strength of the PET drug; (2) If applicable, the name and radioactivity or other measurement of each active pharmaceutical ingredient and each inactive ingredient per batch or per unit of radioactivity or other measurement of the drug product, and a statement of the total radioactivity or other measurement of any dosage unit; (3) A complete list of components designated by names and codes sufficiently specific to indicate any special quality characteristic; (4) Identification of all major pieces of equipment used in production; (5) An accurate statement of the weight or measurement of each component, using the same weight system (metric, avoirdupois, or apothecary) for each component. Reasonable variations 176 are permitted in the amount of component necessary if they are specified in the master production and control records; (6) A statement of action limits on radiochemical yield, i.e., the minimum percentage of yield beyond which investigation and corrective action are required; (7) Complete production and control instructions, sampling and testing procedures, specifications, special notations, and precautions to be followed; and (8) A description of the PET drug product containers, closures, and packaging materials, including a specimen or copy of each label and all other labeling. (c) Batch production and control records. Each time a batch of a PET drug is produced, a unique batch production and control record must be created. The batch production record must include the following information: (1) Name and strength of the PET drug; (2) Identification number or other unique identifier of the specific batch that was produced; (3) The name and radioactivity or other measure of each active pharmaceutical ingredient and each inactive ingredient per batch or per unit of radioactivity or other measurement of the drug product; (4) Each major production step (obtained from the approved appropriate master production and control record); (5) Weights (or other measure of quantity) and identification codes of components; (6) Dates of production steps and times of critical production steps; (7) Identification of major pieces of equipment used in production of the batch; (8) Testing results; (9) Labeling; (10) Initials or signatures of persons performing or checking each significant step in the operation; and (11) Results of any investigations conducted. (d) Area and equipment checks. The production area and all equipment in the production area must be checked to VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

7 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS ensure cleanliness and suitability immediately before use. A record of these checks must be kept. (e) In-process materials controls. Process controls must include control of inprocess materials to ensure that the materials are controlled until required tests or other verification activities have been completed or necessary approvals are received and documented. (f) Process verification. (1) For a PET drug for which each entire batch undergoes full finished-product testing to ensure that the product meets all specifications, process verification, as described in paragraph (f)(2) of this section, is not required. (2) When the results of the production of an entire batch of a PET drug are not fully verified through finishedproduct testing or when only the initial sub-batch in a series is tested, the PET drug producer must demonstrate that the process for producing the PET drug is reproducible and is capable of producing a drug product that meets the predetermined acceptance criteria. Process verification activities and results must be documented. Documentation must include the date and signature of the individual(s) performing the verification, the monitoring and control methods and data, and the major equipment qualified. Subpart G Laboratory Controls What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products? (a) Testing procedures. Each laboratory used to conduct testing of components, in-process materials, and finished PET drug products must have and follow written procedures for the conduct of each test and for the documentation of the results. (b) Specifications and standards. Each laboratory must have sampling and testing procedures designed to ensure that components, in-process materials, and PET drug products conform to appropriate standards, including established standards of identity, strength, quality, and purity. (c) Analytical methods. Laboratory analytical methods must be suitable for their intended use and must be sufficiently sensitive, specific, accurate, and reproducible. (d) Materials. The identity, purity, and quality of reagents, solutions, and supplies used in testing procedures must be adequately controlled. All solutions that you prepare must be properly labeled to show their identity and expiration date. (e) Equipment. All equipment used to perform the testing must be suitable for its intended purposes and capable of producing valid results. (f) Equipment maintenance. Each laboratory must have and follow written procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained, and that these activities are documented. (g) Test records. Each laboratory performing tests related to the production of a PET drug must keep complete records of all tests performed to ensure compliance with established specifications and standards, including examinations and assays, as follows: (1) A suitable identification of the sample received for testing. (2) A description of each method used in the testing of the sample, a record of all calculations performed in connection with each test, and a statement of the weight or measurement of the sample used for each test. (3) A complete record of all data obtained in the course of each test, including the date and time the test was conducted, and all graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, in-process material, or drug product for each lot tested. (4) A statement of the results of tests and how the results compare with established acceptance criteria. (5) The initials or signature of the person performing the test and the date on which the test was performed What must I do to ensure the stability of my PET drug products through expiry? (a) Stability testing program. You must establish, follow, and maintain a written testing program to assess the stability characteristics of your PET drug products. The test methods must be reliable, meaningful, and specific. The VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

8 CFR Ch. I ( Edition) erowe on DSK2VPTVN1PROD with CFR samples tested for stability must be representative of the lot or batch from which they were obtained and must be stored under suitable conditions. (b) Storage conditions and expiration dates. The results of such stability testing must be documented and used in determining appropriate storage conditions and expiration dates and times for each PET drug product you produce. Subpart H Finished Drug Product Controls and Acceptance What controls and acceptance criteria must I have for my finished PET drug products? (a) Specifications. You must establish specifications for each PET drug product, including criteria for determining identity, strength, quality, purity, and, if appropriate, sterility and pyrogens. (b) Test procedures. Before you implement a new test procedure in a specification, you must establish and document the accuracy, sensitivity, specificity, and reproducibility of the procedure. If you use an established compendial test procedure in a specification, you must first verify and document that the test works under the conditions of actual use. (c) Conformance to specifications. Before final release, you must conduct an appropriate laboratory determination to ensure that each batch of a PET drug product conforms to specifications, except for sterility. For a PET drug product produced in sub-batches, before final release, you must conduct an appropriate laboratory determination to ensure that each sub-batch conforms to specifications, except for sterility. (d) Final release procedures. Except as conditional final release is permitted in accordance with paragraph (f) of this section, you must establish and follow procedures to ensure that each batch of a PET drug product is not given final release until the following are done: (1) An appropriate laboratory determination under paragraph (c) of this section is completed; (2) Associated laboratory data and documentation are reviewed and they demonstrate that the PET drug product meets specifications, except for sterility; and (3) A designated qualified individual authorizes final release by dated signature. (e) Sterility testing. Sterility testing need not be completed before final release but must be started within 30 hours after completion of production. The 30-hour requirement may be exceeded due to a weekend or holiday. If the sample for sterility testing is held longer than 30 hours, you must demonstrate that the longer period does not adversely affect the sample and the test results obtained will be equivalent to test results that would have been obtained if the test had been started within the 30-hour time period. Tested samples must be from individual batches and not pooled. If the product fails to meet a criterion for sterility, you must immediately notify all facilities that received the product of the test results and provide any appropriate recommendations. The notification must be documented. Upon completion of an investigation into the failure to meet a criterion for sterility, you must notify all facilities that received the product of the findings from the investigation. (f) Conditional final release. (1) If you cannot complete one of the required finished-product tests for a batch of a PET drug product because of a malfunction involving analytical equipment, you may approve the conditional final release of the product if you meet the following conditions: (i) You have data documenting that preceding consecutive batches, produced using the same methods used for the conditionally released batch, demonstrate that the conditionally released batch will likely meet the established specifications; (ii) You determine that all other acceptance criteria are met; (iii) You retain a reserve sample of the conditionally released batch of drug product; (iv) You promptly correct the malfunction of analytical equipment, complete the omitted test using the reserve sample after the malfunction is corrected, and document that reasonable efforts have been made to prevent recurrence of the malfunction; VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

9 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS (v) If you obtain an out-of-specification result when testing the reserve sample, you immediately notify the receiving facility; and (vi) You document all actions regarding the conditional final release of the drug product, including the justification for the release, all followup actions, results of completed testing, all notifications, and corrective actions to prevent recurrence of the malfunction involving analytical equipment. (2) Even if the criteria in paragraph (f)(1) of this section are met, you may not approve the conditional final release of the product if the malfunction involving analytical equipment prevents the performance of a radiochemical identity/purity test or prevents the determination of the product s specific activity. (3) You may not release another batch of the PET drug product until you have corrected the problem concerning the malfunction of analytical equipment and completed the omitted finished-product test What actions must I take if a batch of PET drug product does not conform to specifications? (a) Rejection of nonconforming product. You must reject a batch of a PET drug product that does not conform to specifications. You must have and follow procedures to identify and segregate the product to avoid mix-ups. You must have and follow procedures to investigate the cause(s) of the nonconforming product. The investigation must include, but is not limited to, examination of processes, operations, records, complaints, and any other relevant sources of information concerning the nonconforming product. (b) Investigation. You must document the investigation of a PET drug product that does not meet specifications, including the results of the investigation and what happened to the rejected PET drug product. (c) Correction of problems. You must take action to correct any identified problems to prevent recurrence of a nonconforming product or other quality problem. (d) Reprocessing. If appropriate, you may reprocess a batch of a PET drug product that does not conform to specifications. If material that does not meet acceptance criteria is reprocessed, you must follow procedures stated in the product s approved application and the finished product must conform to specifications, except for sterility, before final release. Subpart I Packaging and Labeling What are the requirements associated with labeling and packaging PET drug products? (a) A PET drug product must be suitably labeled and packaged to protect the product from alteration, contamination, and damage during the established conditions of shipping, distribution, handling, and use. (b) Labels must be legible and applied so as to remain legible and affixed during the established conditions of processing, storage, handling, distribution, and use. (c) All information stated on each label must also be contained in each batch production record. (d) Labeling and packaging operations must be controlled to prevent labeling and product mix-ups. Subpart J Distribution What actions must I take to control the distribution of PET drug products? (a) Written distribution procedures. You must establish, maintain, and follow written procedures for the control of distribution of PET drug products shipped from the PET drug production facility to ensure that the method of shipping chosen will not adversely affect the identity, purity, or quality of the PET drug product. (b) Distribution records. You must maintain distribution records for each PET drug product that include or refer to the following: (1) The name, address, and telephone number of the receiving facility that received each batch of a PET drug product; (2) The name and quantity of the PET drug product shipped; (3) The lot number, control number, or batch number for the PET drug product shipped; and VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

10 (4) The date and time you shipped the PET drug product. Subpart K Complaint Handling 21 CFR Ch. I ( Edition) How must I maintain records of my production of PET drugs? (a) Record availability. Records must be maintained at the PET drug production facility or another location that is reasonably accessible to responsible officials of the production facility and to employees of FDA designated to perform inspections. (b) Record quality. All records, including those not stored at the inspected establishment, must be legible, stored to prevent deterioration or loss, and readily available for review and copying by FDA employees. (c) Record retention period. You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product. erowe on DSK2VPTVN1PROD with CFR What do I do if I receive a complaint about a PET drug product produced at my facility? (a) Written complaint procedures. You must develop and follow written procedures for the receipt and handling of all complaints concerning the quality or purity of, or possible adverse reactions to, a PET drug product. (b) Complaint review. The procedures must include review by a designated person of any complaint involving the possible failure of a PET drug product to meet any of its specifications and an investigation to determine the cause of the failure. (c) Complaint records. A written record of each complaint must be maintained in a file designated for PET drug product complaints. The record must include the name and strength of the PET drug product, the batch number, the name of the complainant, the date the complaint was received, the nature of the complaint, and the response to the complaint. It must also include the findings of any investigation and followup. (d) Returned products. A PET drug product that is returned because of a complaint or for any other reason may not be reprocessed and must be destroyed in accordance with applicable Federal and State law. Subpart L Records 180 PART 216 PHARMACY COMPOUNDING Subpart A General Provisions [Reserved] Subpart B Compounded Drug Products Sec [Reserved] Drug products withdrawn or removed from the market for reasons of safety or effectiveness. AUTHORITY: 21 U.S.C. 351, 352, 353a, 355, and 371. SOURCE: 64 FR 10944, Mar. 8, 1999, unless otherwise noted. Subpart A General Provisions [Reserved] Subpart B Compounded Drug Products [Reserved] Drug products withdrawn or removed from the market for reasons of safety or effectiveness. The following drug products were withdrawn or removed from the market because such drug products or components of such drug products were found to be unsafe or not effective. The following drug products may not be compounded under the exemptions provided by section 503A(a) of the Federal Food, Drug, and Cosmetic Act: Adenosine phosphate: All drug products containing adenosine phosphate. Adrenal cortex: All drug products containing adrenal cortex. Azaribine: All drug products containing azaribine. Benoxaprofen: All drug products containing benoxaprofen. Bithionol: All drug products containing bithionol. Bromfenac sodium: All drug products containing bromfenac sodium. Butamben: All parenteral drug products containing butamben. Camphorated oil: All drug products containing camphorated oil. Carbetapentane citrate: All oral gel drug products containing carbetapentane citrate. VerDate Mar<15> :14 May 21, 2013 Jkt PO Frm Fmt 8010 Sfmt 8010 Y:\SGML\ XXX

Annex 9 Guide to good storage practices for pharmaceuticals 1

Annex 9 Guide to good storage practices for pharmaceuticals 1 World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Correspondence between ISO 13485:2003 and the US Quality System Regulation

Correspondence between ISO 13485:2003 and the US Quality System Regulation Correspondence between ISO 13485:2003 and the US Quality System Regulation Correspondence between ISO 13485:2003 and the US Quality System Regulation 1 Scope 1.1 General This International Standard specifies

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064587 EudraLex The Rules Governing Medicinal Products

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address: NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a

More information

NSF International Standard / American National Standard. NSF/IPEC/ANSI 363-2014 Good Manufacturing Practices (GMP) for Pharmaceutical Excipients

NSF International Standard / American National Standard. NSF/IPEC/ANSI 363-2014 Good Manufacturing Practices (GMP) for Pharmaceutical Excipients NSF International Standard / American National Standard NSF/IPEC/ANSI 363-2014 Good Manufacturing Practices (GMP) for Pharmaceutical Excipients NSF International, an independent, notfor-profit, non-governmental

More information

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where

More information

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced

More information

GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS

GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Guidance for Industry Current Good Manufacturing Practice Interim Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act DRAFT GUIDANCE This guidance document is

More information

NSF Dietary Supplement

NSF Dietary Supplement NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5

More information

Request for Quality Metrics Guidance for Industry

Request for Quality Metrics Guidance for Industry Request for Quality Metrics Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be

More information

Quality Agreement Template

Quality Agreement Template Quality Agreement Template Prepared by Dan O Leary Ombu Enterprises, LLC 3 Forest Ave. Swanzey, NH 03446 603-209-0600 This document is intended to form the basis for a Supplier Agreement. The document

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

Triangle Compounding 11/2/15

Triangle Compounding 11/2/15 Triangle Compounding 11/2/15 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District 60 Eighth Street NE Atlanta, GA 30309 November 2, 2015 VIA UNITED

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

Company Quality Manual Document No. QM Rev 0. 0 John Rickey Initial Release. Controlled Copy Stamp. authorized signature

Company Quality Manual Document No. QM Rev 0. 0 John Rickey Initial Release. Controlled Copy Stamp. authorized signature Far West Technology, Inc. ISO 9001 Quality Manual Document No.: QM Revision: 0 Issue Date: 27 August 1997 Approval Signatures President/CEO Executive Vice President Vice President/CFO Change Record Rev

More information

Quality Management Systems Manual

Quality Management Systems Manual Washington Division Quality Management Systems Manual ISO 13485:2003 DOCUMENT NUMBER 01-QM-MED REVISION LEVEL 01 PAGE 1 of 40 This manual describes the quality management systems structure at GM Nameplate

More information

PART 1913 RULES OF AGENCY PRACTICE AND PROCEDURE CONCERNING OSHA ACCESS TO EMPLOYEE MEDICAL RECORDS. 29 CFR Ch. XVII (7 1 04 Edition)

PART 1913 RULES OF AGENCY PRACTICE AND PROCEDURE CONCERNING OSHA ACCESS TO EMPLOYEE MEDICAL RECORDS. 29 CFR Ch. XVII (7 1 04 Edition) 1912a.14 1912a.14 Petitions for changes in the rules; complaints. (a) Any interested person shall have the right to petition for the issuance, amendment, or repeal of rules published in this part. Any

More information

The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies.

The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies. 1 NABP Model State Pharmacy Act & Model Rules Appendix B Good Compounding Practices Applicable to State Licensed Pharmacies The following Good Compounding Practices (GCPs) are meant to apply only to the

More information

Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP

Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Document issued on: June 2004 U.S. Department of Health and Human Services Food and Drug Administration

More information

Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles

Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles Introduction 37 General considerations 39 Glossary

More information

Annex 2 Good trade and distribution practices for pharmaceutical starting materials

Annex 2 Good trade and distribution practices for pharmaceutical starting materials World Health Organization WHO Technical Report Series, No. 917, 2003 Annex 2 ood trade and distribution practices for pharmaceutical starting materials Introductory note 36 Scope 37 eneral considerations

More information

Library Guide: Pharmaceutical GMPs

Library Guide: Pharmaceutical GMPs Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA

More information

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer

More information

Supplier Quality Assurance

Supplier Quality Assurance Supplier Quality Assurance Preface We strive to continually improve our process performance by meeting quality objectives. It is imperative that our suppliers operate under the zero defects and 100% on

More information

Pharmaceutical Wholesaler Site Inspection Checklist

Pharmaceutical Wholesaler Site Inspection Checklist Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:

More information

21 Code of Federal Regulations Parts 210 and 211

21 Code of Federal Regulations Parts 210 and 211 21 Code of Federal Regulations Parts 210 and 211 Part 210 - CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL Part 211 - CURRENT GOOD MANUFACTURING

More information

Defense Acquisition Regulations System, DOD 252.227 7018

Defense Acquisition Regulations System, DOD 252.227 7018 Defense Acquisition Regulations System, DOD 252.227 7018 *****Enter none when all data or software will be submitted without restrictions. Date lllllllllllllllllllll Printed Name and Title lllllllllll

More information

MeriCal Quality Profile

MeriCal Quality Profile January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.

More information

TABLE OF CONTENTS COMMITTEE MEMBERS... 4 ABBREVIATION LIST... 7 DEFINITIONS... 8 INTRODUCTION... 10 GENERAL PROVISIONS... 11

TABLE OF CONTENTS COMMITTEE MEMBERS... 4 ABBREVIATION LIST... 7 DEFINITIONS... 8 INTRODUCTION... 10 GENERAL PROVISIONS... 11 Prepared by Nuclear Pharmacy Compounding Practice Committee Section on Nuclear Pharmacy Practice Academy of Pharmacy Practice and Management (APPM) American Pharmaceutical Association (APhA) Nuclear Pharmacy

More information

Example of a food company quality

Example of a food company quality Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.

More information

FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7356.002E

FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7356.002E SUBJECT: COMPRESSED MEDICAL GASES Cross-reference: 7356.002 (version 02/01/2002) IMPLEMENTATION DATE March 15, 2015 COMPLETION DATE March 15, 2018 DATA REPORTING PRODUCT CODES Medical Gases Industry codes:

More information

Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1

Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1 Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and

More information

References to Computer and Software in FDA s CGTPs (Final Rule and Draft Guidance) for HCT/Ps Preamble to the CGTP Final Rule

References to Computer and Software in FDA s CGTPs (Final Rule and Draft Guidance) for HCT/Ps Preamble to the CGTP Final Rule Preamble to the CGTP Final Rule Pages 68626-68627 Computers Proposed 1271.160(e) would require establishments to validate computer software used as part of manufacturing or tracking or for maintaining

More information

Documents, Records and Change Control

Documents, Records and Change Control Documents, Records and Change Control Lori S. Lawless Medical Device Specialist Food and Drug Administration Baltimore District Office Lori.Lawless@fda.hhs.gov (410) 779-5442 May 13-14, 2008 Baltimore

More information

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration & Preventative Maintenance Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration: A comparison of two instruments or measuring devices one of which is a standard of known

More information

ISO/IEC 17025 QUALITY MANUAL

ISO/IEC 17025 QUALITY MANUAL 1800 NW 169 th Pl, Beaverton, OR 97006 Revision F Date: 9/18/06 PAGE 1 OF 18 TABLE OF CONTENTS Quality Manual Section Applicable ISO/IEC 17025:2005 clause(s) Page Quality Policy 4.2.2 3 Introduction 4

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

BQ-9000 Quality Management System. Marketer Requirements

BQ-9000 Quality Management System. Marketer Requirements BQ-9000 Quality Management System Marketer Requirements Revision 5 Effective Date: February 1, 2009 2009 National Biodiesel Board This requirements document has been prepared by the National Biodiesel

More information

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 9.1 Status : APPROVED Effective: 12/11/2014 Page 2 of 23 Quality Manual Table of Contents

More information

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations

More information

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 9.2 Status : APPROVED Effective: 9/25/2015 Page 2 of 23 Quality Manual Table of Contents

More information

NH Laws / Rules Regarding Limited Retail Drug Distributors

NH Laws / Rules Regarding Limited Retail Drug Distributors NH Laws / Rules Regarding Limited Retail Drug Distributors 318:1, VII-a. "Limited retail drug distributor'' means a distributor of legend devices or medical gases delivered directly to the consumer pursuant

More information

BQ-9000 Quality Management System. Certified Marketer Requirements

BQ-9000 Quality Management System. Certified Marketer Requirements BQ-9000 Quality Management System Certified Marketer Requirements Revision 3 Effective Date: February 1, 2007 This requirements document has been prepared by the National Biodiesel Accreditation Commission,

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

Sandoz Private Limited 10/22/15

Sandoz Private Limited 10/22/15 Sandoz Private Limited 10/22/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Warning Letter VIA UPS WL: 320-16-01 October 22, 2015

More information

[See Rules 74,74-A, 74-B, 78 and 78-A] A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL

[See Rules 74,74-A, 74-B, 78 and 78-A] A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL 29 [SCHEDULE U [See Rules 74,74-A, 74-B, 78 and 78-A] I. Particulars to the shown in /manufacturing Records A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL 1. Serial number. 2. Name of the

More information

SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS

SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS GAZETTE OF INDIA EXTRAORDINARY, PART II-SECTION 3, SUB-SECTION (i)] MINISTRY OF HEALTH

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION

CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed

More information

How To Inspect A Blood Bank

How To Inspect A Blood Bank Site visit inspection report on compliance with HTA minimum standards Belfast Cord Blood Bank HTA licensing number 11077 Licensed for the procurement, processing, testing, storage, distribution and import/export

More information

[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS.

[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. [SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. Note: - To achieve the objectives listed below, each

More information

Subpart C Administrative Wage Garnishment

Subpart C Administrative Wage Garnishment Small Business Administration 140.11 (m) Where an IRS tax refund offset is sought, SBA must follow the Department of the Treasury s regulations governing offset of a past-due, legally enforceable debt

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

COMMISSION DIRECTIVE 2003/94/EC

COMMISSION DIRECTIVE 2003/94/EC L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL

More information

AS9100 Quality Manual

AS9100 Quality Manual Origination Date: August 14, 2009 Document Identifier: Quality Manual Revision Date: 8/5/2015 Revision Level: Q AS 9100 UNCONTROLLED IF PRINTED Page 1 of 17 1 Scope Advanced Companies (Advanced) has established

More information

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

5 CFR Ch. I (1 1 01 Edition) SOURCE: 60 FR 43943, Aug. 23, 1995, unless otherwise noted. otherwise noted.

5 CFR Ch. I (1 1 01 Edition) SOURCE: 60 FR 43943, Aug. 23, 1995, unless otherwise noted. otherwise noted. Pt. 430 appointment may not be used to fill an agency s regular positions on a continuing basis. (3) Schedule B appointments must be made in the same manner as merit staffing requirements prescribed for

More information

Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products

Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products U.S. Department of Health and Human Services Food and Drug Administration

More information

ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE

ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL

More information

PRODUCT CERTIFICATION REQUIREMENTS

PRODUCT CERTIFICATION REQUIREMENTS PRODUCT CERTIFICATION REQUIREMENTS SIRIM QAS International Product Certification Page 1 of 14 QUALITY SYSTEM 1. GENERAL 1.1 This document defines the responsibilities and obligations of the Licensee with

More information

Subpart D Executive Development

Subpart D Executive Development Office of Personnel Management 430.102 Subpart D Executive Development 412.401 Continuing executive development. (a) Each agency must establish a program or programs for the continuing development of its

More information

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants USP Pharmaceutical Ingredient Supplier Qualification Program Manual for Participants UNITED STATES PHARMACOPEIA Drug Substance Supplier Qualification Program ICE This manual provides information to drug

More information

Guide to Master Formulae WHO/FWC/IVB/QSS/VQR

Guide to Master Formulae WHO/FWC/IVB/QSS/VQR WHO/FWC/IVB/QSS/VQR 2011 This guidance document GUIDE TO MASTER FORMULAE is one of a series developed by WHO/FWC/IVB Quality, Safety & Standards team upon request from the manufacturers members of the

More information

Department of Veterans Affairs 36.4303

Department of Veterans Affairs 36.4303 Department of Veterans Affairs 36.4303 is added to principal during the graduation period without regard to the original maximum dollar amount of guaranty. (Authority: 38 U.S.C. 3703(b) (d)) (i) The amount

More information

Checklist. Standard for Medical Laboratory

Checklist. Standard for Medical Laboratory Checklist Standard for Medical Laboratory Name of hospital..name of Laboratory..... Name. Position / Title...... DD/MM/YY.Revision... 1. Organization and Management 1. Laboratory shall have the organizational

More information

Office of Personnel Management 1699.70

Office of Personnel Management 1699.70 Office of Personnel Management 1699.70 PART 1653 FORMS AUTHORITY: 5 U.S.C. 8913; 40 U.S.C. 486(c); 48 CFR 1.301. 1653.000 FEHBP forms. The following forms specified in FAR subparts 53.2 and 53.3 are applicable

More information

RTP s NUCLEAR QUALITY ASSURANCE PROGRAM

RTP s NUCLEAR QUALITY ASSURANCE PROGRAM RTP s NUCLEAR QUALITY ASSURANCE PROGRAM RTP operates under one quality program, whether you purchase products that are commercial grade, nuclear safety-related or industrial safety compliant (IEC 61508).

More information

Guidance for Industry Bar Code Label Requirements Questions and Answers

Guidance for Industry Bar Code Label Requirements Questions and Answers Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation

More information

NIST HANDBOOK 150 CHECKLIST

NIST HANDBOOK 150 CHECKLIST NIST HANDBOOK 150 CHECKLIST Instructions to the Assessor: This checklist addresses the general accreditation criteria prescribed in NIST Handbook 150, NVLAP Procedures and General Requirements (2006 edition).

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain

16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain 16.19.10.11 PUBLIC HEALTH CLINICS: A. CLINIC LICENSURE: (1) All clinics where dangerous drugs are administered, distributed or dispensed shall obtain a limited drug permit as described in Section 61-11-14

More information

GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT

GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT GOOD MANUFACTURING PRACTICES GUIDANCE DOCUMENT Natural Health Products Directorate August 2006 Version 2.0 Our mission is to help the people of Canada maintain and improve their health, while respecting

More information

PARTS 1291 1299 [RESERVED]

PARTS 1291 1299 [RESERVED] National Archives and Records Administration 1290.8 (e) Unless the Review Board in its sole discretion directs otherwise, records that are identified with respect to a particular person shall include all

More information

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist

More information

Industrial Testing and Certification Requirements For Import Shipping Process

Industrial Testing and Certification Requirements For Import Shipping Process 68328 Federal Register / Vol. 73, No. 223 / Tuesday, November 18, 2008 / Rules and Regulations 29. Section 772.1 is amended by revising the definition of transfer to read as follows: 772.1 Definitions

More information

SUPPLIER QUALITY MANAGEMENT SYSTEM QUESTIONNAIRE

SUPPLIER QUALITY MANAGEMENT SYSTEM QUESTIONNAIRE Company Name Street Address City, State, Zip code Phone Number Fax Company Website Email Address ORGANIZATION NAME PHONE NUMBER EMAIL ADDRESS President/CEO General Manager Engineering Manager Production

More information

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs. 15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2

More information

1083.1 QUALITY MANAGEMENT SYSTEM

1083.1 QUALITY MANAGEMENT SYSTEM BRIEFING 1083.1 Quality Management System. USP is proposing a new series of Good Distribution Practices (GDP) general chapters, which were developed as a result of reviewing two existing general chapters,

More information

Cartel Electronics. AS 9100 Quality Systems Manual

Cartel Electronics. AS 9100 Quality Systems Manual Cartel Electronics AS 9100 Quality Systems Manual 1900 C Petra Lane Placentia, California 92870 Introduction Cartel Electronics, as a global supplier to the aviation, space, and space industries, has developed

More information

IMP management at site. Dmitry Semenyuta

IMP management at site. Dmitry Semenyuta IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records

More information

Quality Manual. DuraTech Industries, Inc. 3216 Commerce Street La Crosse, WI 54603 MANUAL SERIAL NUMBER 1

Quality Manual. DuraTech Industries, Inc. 3216 Commerce Street La Crosse, WI 54603 MANUAL SERIAL NUMBER 1 Quality Manual Approval Page Document: QA1000 Issue Date: 5/29/1997 Page 1 of 17 Revision Date: 5/20/2013 DuraTech Industries, Inc. 3216 Commerce Street La Crosse, WI 54603 MANUAL SERIAL NUMBER 1 This

More information

sions with that effect will lose the benefit of the safe harbor for appropriate use of Appendix H model forms. A person is not required

sions with that effect will lose the benefit of the safe harbor for appropriate use of Appendix H model forms. A person is not required Federal Reserve System (l) Conducting a periodic evaluation of its own practices, consumer reporting agency practices of which the furnisher is aware, investigations of disputed information, corrections

More information

State Meat and Poultry Inspection (MPI) Program Laboratory Quality Management System Checklist

State Meat and Poultry Inspection (MPI) Program Laboratory Quality Management System Checklist This checklist is intended to help laboratories improve the quality of their testing programs with regard to meat and poultry testing samples, in order to ensure those laboratories are at least equal to

More information

Quality assurance of pharmaceuticals

Quality assurance of pharmaceuticals QAPPR 12/16/06 12:10 PM Page i Quality assurance of pharmaceuticals A compendium of guidelines and related materials Volume 2, 2nd updated edition Good manufacturing practices and inspection QAPPR 12/16/06

More information

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Investigational Drugs: Investigational Drugs and Biologics

Investigational Drugs: Investigational Drugs and Biologics : I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place

More information

GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD)

GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD) MEDICAL DEVICE CONTROL DIVISION Ministry of Health, Malaysia Regulatory Requirements for Medical Device Safety & Performance GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES (GDPMD) DRAFT DRAFT 1 September

More information

Corden Pharma Latina S.p.A. 5/20/16

Corden Pharma Latina S.p.A. 5/20/16 Corden Pharma Latina S.p.A. 5/20/16 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Via UPS Warning Letter 320-16-14 Return Receipt Requested

More information

Surgi Manufacturing Quality Manual

Surgi Manufacturing Quality Manual Surgi Manufacturing Page 1 of 18 Approvals: QA: Eng. Mgt. : A Date: 18Aug98 1. Introduction... 4 1.1 Scope... 4 1.2 Purpose... 4 1.3 Authority... 4 1.4 Issue of the Manual... 4 1.5 Amendments... 4 1.6

More information

Quality Management System Manual

Quality Management System Manual Quality Management System Manual Assurance ISO / AS Manual Quality Management System EXCEEDING ALL EXPECTATIONS Since our inception in 1965, Swiss-Tech has supplied the medical, aerospace, hydraulic, electronic

More information

MEDICAL DEVICE GUIDANCE

MEDICAL DEVICE GUIDANCE May 2014 MEDICAL DEVICE GUIDANCE GN-23: Guidance on Labelling for Medical Devices PREFACE This document is intended to provide general guidance. Although we have tried to ensure that the information contained

More information

Supplier Quality Agreements

Supplier Quality Agreements Supplier Quality Agreements Dan O Leary CBA, CQA, CQE, CRE, SSBB, CIRM President Ombu Enterprises, LLC Dan@OmbuEnterprises.com www.ombuenterprises.com 603-209-0600 1 Speaker Biography Dan O Leary Dan O

More information